YAPING GAN^1,2,#, TING LIU^3,#, WEIFENG FENG^1,#, LIANG WANG⁴, LI LI⁵, YINGXIA NING^1,*

Oncology Research, Vol.31, No.3, pp. 333-343, 2023, DOI:10.32604/or.2023.028694

Abstract Various therapeutic strategies have been developed to overcome ovarian cancer. However, the prognoses resulting from these strategies are still unclear. In the present work, we screened 54 small molecule compounds approved by the FDA to identify novel agents that could inhibit the viability of human epithelial ovarian cancer cells. Among these, we identified disulfiram (DSF), an old alcohol-abuse drug, as a potential inducer of cell death in ovarian cancer. Mechanistically, DSF treatment significantly reduced the expression of the anti-apoptosis marker B-cell lymphoma/leukemia-2 (Bcl-2) and increase the expression of the apoptotic molecules Bcl2 associated X (Bax) and cleaved caspase-3 to promote… More >

KAMILA CZUBAK-PROWIZOR^*, MARIA SWIATKOWSKA

BIOCELL, Vol.47, No.4, pp. 731-737, 2023, DOI:10.32604/biocell.2023.025677

Abstract Junctional adhesion molecule-A (JAM-A), also known as the F11 receptor (F11R), is one of the tight junction components. JAM-A is a transmembrane glycoprotein that regulates many cellular processes, i.e., angiogenesis, leukocyte transendothelial migration, intercellular permeability, epithelial-to-mesenchymal transition, and platelet activation. Of note, it is involved in the pathogenesis of various cancer types, including gynecological cancers. Only a few studies are available about this cancer type. Observed aberrant JAM-A expression in gynecological cancers correlates with poor patient prognosis. To the best of our knowledge, conflicting JAM-A roles in various cancer types suggest that its involvement is complex and tumor-type specific. The… More >

SHUTING GU^1,2,#, JINGYI QIN^3,#, SAINAN GAO¹, ZHEN WANG^1,4, QI MENG^1,4, YAN LI^1,4, BING LU⁵, SONGLIN ZHOU^1,2,*, YUNZHAO XU^1,6,*

BIOCELL, Vol.46, No.3, pp. 689-697, 2022, DOI:10.32604/biocell.2022.016225

Abstract Recently, abnormal expression of KIAA1199 has been detected in Epithelial Ovarian Cancer (EOC). However, the underlined anti-ovarian cancer mechanism of KIAA1199 remains to be enlightened. In our study, we performed to elucidate the effects of KIAA1199 on the advanced biological behavior of EOC cells through activation of the IL-6/STAT3 pathway. Confirmed by immunohistochemistry, KIAA1199 was highly expressed in ovarian borderline and malignant epithelial tumors. A retrospective analysis found that EOC patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression. Mechanistically, IL-6 was used to stimulate EOC cells, and the expression of… More >

AJIT C. DHADVE^1,2, PRITHA RAY^1,2

BIOCELL, Vol.46, No.1, pp. 75-86, 2022, DOI:10.32604/biocell.2022.016346

Abstract Progression, relapse, and therapy resistance are the most challenging features of cancer therapy that have been postulated to be driven by Cancer Stem Cell (CSC) population. This enigmatic subpopulation of cancer cells has therefore emerged as promising therapeutic candidate. We earlier reported enrichment of CSC-like side population (SP) with increasing resistance towards Cisplatin and Paclitaxel either alone or in combination in epithelial ovarian cancer (EOC) cells. This SP population is a small proportion of the total population of cancer cells characterised with high expression of drug transporters, a unique feature of stem cells and thereby can be isolated through their… More >